Verdeso

(Desonide)

ApprovedSmall molecule

PPadagis LLC

Verdeso is one of 54 small molecule programs targeting Psoriasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

PsoriasisApproved

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Verdeso

PPadagis LLC

Approved

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis1 trial

Proton Pump Inhibitors Use in Patients With Psoriasis

Withdrawn·EEMS·Phase 4·NCT02624544

Hyperpigmentation1 trial

Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

Completed·UUniversidad Autonoma de San Luis Potosí·Phase 4·NCT01542138·28 enrolled

Atopic Dermatitis1 trial

Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis

Unknown status·NNeoStrata Company, Inc.·Phase 3·NCT02286700·42 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

DESONIDE

NDA NDA017010

Jan 1, 1982

DESONIDE

NDA NDA017426

Dec 14, 1984

DESOWEN

NDA NDA019048

Sep 19, 2006

VERDESO

NDA NDA021978

Oct 20, 2006

DESONATE

NDA NDA021844

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Desonide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Desonide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Desonide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021844). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Verdeso. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Padagis LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPadagis LLC

Patent Landscape[5]

Patent Cliff

Aug 13, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8460641Aug 13, 2027

Verdeso

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis1 trial

Hyperpigmentation1 trial

Atopic Dermatitis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News